EPISODE · Dec 30, 2022 · 20 MIN
DESTINY-Breast04 Study Discussion with Dr. Shanu Modi
from Oncology Brothers: Practice-Changing Cancer Discussions · host Oncology Brothers
Discussing the DESTINY-Breast04 study which resulted in a paradigm shift, with the introduction of low HER2 positive breast cancer, and further approval of Trastuzumab Deruxtecan (T-DXd). In discussion with the lead author, Dr. Shanu Modi - Professor of Medicine at Memorial Sloan Kettering Cancer Center. Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at [email protected]
What this episode covers
Discussing the DESTINY-Breast04 study which resulted in a paradigm shift, with the introduction of low HER2 positive breast cancer, and further approval of Trastuzumab Deruxtecan (T-DXd). In discussion with the lead author, Dr. Shanu Modi - Professor of Medicine at Memorial Sloan Kettering Cancer Center. Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at [email protected]
NOW PLAYING
DESTINY-Breast04 Study Discussion with Dr. Shanu Modi
No transcript for this episode yet
Similar Episodes
Mar 31, 2026 ·54m
Mar 27, 2026 ·14m
Mar 24, 2026 ·42m
Mar 20, 2026 ·42m
Mar 17, 2026 ·41m
Mar 13, 2026 ·44m